Login to Your Account



Ampligen Patient Hunger Strike; Hemispherx Takes CRL Tailspin

By Randy Osborne
Staff Writer

Tuesday, February 5, 2013

Hemispherx Biopharma Inc.'s complete response letter from the FDA in the wake of a negative advisory panel review of Ampligen for chronic fatigue syndrome (CFS) left the company weighing its chances of success in appealing the decision, and left patients without options.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription